Simon J. Holton

Surface-mutagenesis strategies to enable structural biology crystallization platforms

Martina Schaefer, Vera Pütter, André Hilpmann, Ursula Egner et autres

A key prerequisite for the successful application of protein crystallography in drug discovery is to establish a robust crystallization system for a new drug-target protein fast enough to deliver crystal structures when the first inhibitors have been identified in the hit-finding campaign …

de (code pays fourni par la source)

Figure S2 from Inhibition of BUB1 Kinase by BAY 1816032 Sensitizes Tumor Cells toward Taxanes, ATR, and PARP Inhibitors In Vitro and In Vivo

Gerhard Siemeister, Anne Mengel, Amaury E. Fernández‐Montalván, Wilhelm Bone et autres

Cellular assays

Supplementary Table S5 from Inhibition of BUB1 Kinase by BAY 1816032 Sensitizes Tumor Cells toward Taxanes, ATR, and PARP Inhibitors In Vitro and In Vivo

Gerhard Siemeister, Anne Mengel, Amaury E. Fernández‐Montalván, Wilhelm Bone et autres

Exposure data from xenograft studies

Supplementary Table S2 from Inhibition of BUB1 Kinase by BAY 1816032 Sensitizes Tumor Cells toward Taxanes, ATR, and PARP Inhibitors In Vitro and In Vivo

Gerhard Siemeister, Anne Mengel, Amaury E. Fernández‐Montalván, Wilhelm Bone et autres

Anti-proliferative cell line profile of BAY 1816032

Figure S3 from Inhibition of BUB1 Kinase by BAY 1816032 Sensitizes Tumor Cells toward Taxanes, ATR, and PARP Inhibitors In Vitro and In Vivo

Gerhard Siemeister, Anne Mengel, Amaury E. Fernández‐Montalván, Wilhelm Bone et autres

Cell cycle analyses

Supplementary Table S6 from Inhibition of BUB1 Kinase by BAY 1816032 Sensitizes Tumor Cells toward Taxanes, ATR, and PARP Inhibitors In Vitro and In Vivo

Gerhard Siemeister, Anne Mengel, Amaury E. Fernández‐Montalván, Wilhelm Bone et autres

Crystallographic data

Supplementary Table S4 from Inhibition of BUB1 Kinase by BAY 1816032 Sensitizes Tumor Cells toward Taxanes, ATR, and PARP Inhibitors In Vitro and In Vivo

Gerhard Siemeister, Anne Mengel, Amaury E. Fernández‐Montalván, Wilhelm Bone et autres

In vitro combination results

Supplementary Table S3 from Inhibition of BUB1 Kinase by BAY 1816032 Sensitizes Tumor Cells toward Taxanes, ATR, and PARP Inhibitors In Vitro and In Vivo

Gerhard Siemeister, Anne Mengel, Amaury E. Fernández‐Montalván, Wilhelm Bone et autres

Kinase selectivity of 2OH-BNP1 in comparison to BAY 1816032

Figure S2 from Inhibition of BUB1 Kinase by BAY 1816032 Sensitizes Tumor Cells toward Taxanes, ATR, and PARP Inhibitors In Vitro and In Vivo

Gerhard Siemeister, Anne Mengel, Amaury E. Fernández‐Montalván, Wilhelm Bone et autres

Cellular assays

Supplementary Table S5 from Inhibition of BUB1 Kinase by BAY 1816032 Sensitizes Tumor Cells toward Taxanes, ATR, and PARP Inhibitors In Vitro and In Vivo

Gerhard Siemeister, Anne Mengel, Amaury E. Fernández‐Montalván, Wilhelm Bone et autres

Exposure data from xenograft studies

Supplementary Table S4 from Inhibition of BUB1 Kinase by BAY 1816032 Sensitizes Tumor Cells toward Taxanes, ATR, and PARP Inhibitors In Vitro and In Vivo

Gerhard Siemeister, Anne Mengel, Amaury E. Fernández‐Montalván, Wilhelm Bone et autres

In vitro combination results

Supplementary Table S3 from Inhibition of BUB1 Kinase by BAY 1816032 Sensitizes Tumor Cells toward Taxanes, ATR, and PARP Inhibitors In Vitro and In Vivo

Gerhard Siemeister, Anne Mengel, Amaury E. Fernández‐Montalván, Wilhelm Bone et autres

Kinase selectivity of 2OH-BNP1 in comparison to BAY 1816032